<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<References xsi:schemaLocation="http://www.iedb.org/schema/CurationSchema http://beta.iedb.org/schema/Curation.xsd" xmlns="http://www.iedb.org/schema/CurationSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <Reference>
        <ReferenceId>834</ReferenceId>
        <DateLastUpdated>2020-09-10-07:00</DateLastUpdated>
        <Article>
            <PubmedId>10811862</PubmedId>
            <Abstract>CD8(+) cytotoxic T lymphocytes (CTLs) recognize antigen in the context of major histocompatibility complex (MHC) class I molecules. Class I epitopes have been classified as dominant or subdominant depending on the magnitude of the CTL response to the epitope. In this report, we have examined the in vitro memory CTL response of H-2(d) haplotype murine CD8(+) T lymphocytes specific for a dominant and subdominant epitope of influenza hemagglutinin using activation marker expression and staining with soluble tetrameric MHC-peptide complexes. Immune CD8(+) T lymphocytes specific for the dominant HA204-210 epitope give rise to CTL effectors that display activation markers, stain with the HA204 tetramer, and exhibit effector functions (i.e., cytolytic activity and cytokine synthesis). In contrast, stimulation of memory CD8(+) T lymphocytes directed to the subdominant HA210-219 epitope results in the generation of a large population of activated CD8(+) T cells that exhibit weak cytolytic activity and fail to stain with the HA210 tetramer. After additional rounds of restimulation with antigen, the HA210-219-specific subdominant CD8(+) T lymphocytes give rise to daughter cells that acquire antigen-specific CTL effector activity and transition from a HA210 tetramer-negative to a tetramer-positive phenotype. These results suggest a novel mechanism to account for weak CD8(+) CTL responses to subdominant epitopes at the level of CD8(+) T lymphocyte differentiation into effector CTL. The implications of these findings for CD8(+) T lymphocyte activation are discussed.</Abstract>
            <ArticleYear>2000</ArticleYear>
            <ArticlePages>1687-98</ArticlePages>
            <ArticleTitle>Incomplete CD8(+) T lymphocyte differentiation as a mechanism for subdominant cytotoxic T lymphocyte responses to a viral antigen.</ArticleTitle>
            <Authors>
                <Author>
                    <LastName>Spencer</LastName>
                    <ForeName>J V</ForeName>
                </Author>
                <Author>
                    <LastName>Braciale</LastName>
                    <ForeName>T J</ForeName>
                </Author>
            </Authors>
            <Affiliations>Beirne B. Carter Center for Immunology Research, University of Virginia, Charlottesville, Virginia 22906, USA.</Affiliations>
            <ArticleChemicalList>Antigens, Viral;Epitopes;H-2 Antigens;Hemagglutinin Glycoproteins, Influenza Virus;Immunodominant Epitopes</ArticleChemicalList>
            <ArticleMeshHeadingsList>Animals; Antigens, Viral; CD8-Positive T-Lymphocytes(cytology; immunology); Cell Differentiation; Cell Line; Clonal Anergy; Cytotoxicity, Immunologic; Epitopes(chemistry); Female; H-2 Antigens(chemistry); Hemagglutinin Glycoproteins, Influenza Virus; Immunodominant Epitopes(chemistry); Lymphocyte Activation; Mice; Mice, Inbred BALB C; Protein Structure, Quaternary; T-Lymphocytes, Cytotoxic(cytology; immunology)</ArticleMeshHeadingsList>
            <Journal>
                <Volume>191</Volume>
                <Issue>10</Issue>
                <Title>The Journal of experimental medicine</Title>
                <Issn>0022-1007</Issn>
                <MedlineTa>J Exp Med</MedlineTa>
            </Journal>
        </Article>
        <Epitopes>
            <Epitope>
                <EpitopeName>HA204-212</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>LYQNVGTYV</LinearSequence>
                        <StartingPosition>204</StartingPosition>
                        <EndingPosition>212</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>P03451.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>11320</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Author communication</LocationOfData>
                <EpitopeId>40910</EpitopeId>
                <ReferenceStartingPosition>204</ReferenceStartingPosition>
                <ReferenceEndingPosition>212</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <Assays>
                    <TCell>
                        <LocationOfData>Figures 2A and 4, table 1</LocationOfData>
                        <TCellId>9177</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>LYQNVGTYV</LinearSequence>
                                            <StartingPosition>204</StartingPosition>
                                            <EndingPosition>212</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>P03451.1</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>11320</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>HA A-</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <RecombinantOrganism>
                                        <SubType>Recombinant Organism</SubType>
                                        <RecombinantOrganismId>10245</RecombinantOrganismId>
                                    </RecombinantOrganism>
                                </ImmunogenContainingObject>
                                <Route>Intraperitoneal (i.p.)</Route>
                            </FirstInVivoProcess>
                            <InVitroAdministration>
                                <ProcessType>Restimulation in vitro</ProcessType>
                                <ResponderCellType>Splenocyte</ResponderCellType>
                                <StimulatorCellType>Splenocyte</StimulatorCellType>
                            </InVitroAdministration>
                            <ImmunizationComments>To create the cells used in this assay, mice were immunized with a recombinant vaccinia virus expressing the A/Japan/305/57 HA protein lacking the immunodominant transmembrane region (HA A-). Splenocytes were then stimulated in vitro 1, 2, or 3 times with APC infected with Influenza strain A/Ann Arbor/57 which differs from the A/Japan/305/57 sequence at aa 215 rendering it unrecognizable by CTLs specific for HA 210-219. This protocol was developed to select for HA 204-212 specific CTLS.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>T cell CD8+</CellType>
                            <CellCultureConditions>Short Term Restimulated</CellCultureConditions>
                        </EffectorCells>
                        <MhcAllele>
                            <MhcAlleleId>124</MhcAlleleId>
                            <MhcEvidenceCode>T cell assay -Single MHC type present</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>HA204-212</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>LYQNVGTYV</LinearSequence>
                                        <StartingPosition>204</StartingPosition>
                                        <EndingPosition>212</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P03451.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>11320</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>47</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>To create the cells used in this assay, mice were immunized with a recombinant vaccinia virus expressing the A/Japan/305/57 HA protein lacking the immunodominant transmembrane region. Splenocytes were then stimulated in vitro 1, 2 or 3 times with APC infected with Influenza strain A/Ann Arbor/57 which differs from the A/Japan/305/57 sequence at aa 215 rendering it unrecognizable by CTLs specific for HA 210-219. This protocol was developed to select for HA 204-212 specific CTLS which bound tetramers presenting the epitope. The number of CD8+ tetramer + cells increased with each round of in vitro stimulation with 97% of the cells being positive after three stimulations.The tetramer positive cells were also increasingly of the activated phenotype, CD44hi CD62L lo (97% of the cells after three stimulations).</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Figures 3C and 5C</LocationOfData>
                        <TCellId>10620</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>LYQNVGTYV</LinearSequence>
                                            <StartingPosition>204</StartingPosition>
                                            <EndingPosition>212</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>P03451.1</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>11320</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>HA A-</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <RecombinantOrganism>
                                        <SubType>Recombinant Organism</SubType>
                                        <RecombinantOrganismId>10245</RecombinantOrganismId>
                                    </RecombinantOrganism>
                                </ImmunogenContainingObject>
                                <Route>Intraperitoneal (i.p.)</Route>
                            </FirstInVivoProcess>
                            <InVitroAdministration>
                                <ProcessType>Restimulation in vitro</ProcessType>
                                <ResponderCellType>Splenocyte</ResponderCellType>
                                <StimulatorCellType>Splenocyte</StimulatorCellType>
                            </InVitroAdministration>
                            <ImmunizationComments>To create the CTL line used in this assay, mice were immunized with a recombinant vaccinia virus expressing the A/Japan/305/57 HA protein lacking the immunodominant transmembrane region (HA A-). Splenocytes were then stimulated in vitro with APC infected with Influenza strain A/Ann Arbor/57 which differs from the A/Japan/305/57 sequence at aa 215 rendering it unrecognizable by CTLs specific for HA 210-219. This protocol was developed to select for HA 204-212 specific CTLS. In vitro restimulation was performed up to three times at 14 day intervals.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>T cell CD8+</CellType>
                            <CellCultureConditions>Cell Line / Clone</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Other</CellTissueType>
                            <CellType>P815-Mast cell</CellType>
                            <CellCultureConditions>Cell Line / Clone</CellCultureConditions>
                            <AutologousOrSyngeneic>N</AutologousOrSyngeneic>
                            <SourceOrganismId>10090</SourceOrganismId>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>124</MhcAlleleId>
                            <MhcEvidenceCode>T cell assay -Single MHC type present</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>HA204-212</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>LYQNVGTYV</LinearSequence>
                                        <StartingPosition>204</StartingPosition>
                                        <EndingPosition>212</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P03451.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>11320</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>53</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>IFNg was produced in response to epitope presentation  by a CTL cell line restimulated in vitro either 1 or 3 times with influenza virusA/Ann Arbor/57 which differs from the A/Japan/305/57 sequence at aa 215 rendering it unrecognizable by CTLs specific for HA 210-219. This protocol was developed to select for HA 204-212 specific CTLS. This IFNg production was higher than that produced by a HA210-219 specific CTL line similarly stimulated in vitro after one round of stimulation, but was similar after three rounds of in vitro stimulation with the corresponding epitope.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Figures 3A, 5A,  and 8A</LocationOfData>
                        <TCellId>9184</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>LYQNVGTYV</LinearSequence>
                                            <StartingPosition>204</StartingPosition>
                                            <EndingPosition>212</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>P03451.1</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>11320</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>HA A-</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <RecombinantOrganism>
                                        <SubType>Recombinant Organism</SubType>
                                        <RecombinantOrganismId>10245</RecombinantOrganismId>
                                    </RecombinantOrganism>
                                </ImmunogenContainingObject>
                                <Route>Intraperitoneal (i.p.)</Route>
                            </FirstInVivoProcess>
                            <InVitroAdministration>
                                <ProcessType>Restimulation in vitro</ProcessType>
                                <ResponderCellType>Splenocyte</ResponderCellType>
                                <StimulatorCellType>Splenocyte</StimulatorCellType>
                            </InVitroAdministration>
                            <ImmunizationComments>To create the CTL line used in this assay, mice were immunized with a recombinant vaccinia virus expressing the A/Japan/305/57 HA protein lacking the immunodominant transmembrane region (HA A-). Splenocytes were then stimulated in vitro with APC infected with Influenza strain A/Ann Arbor/57 which differs from the A/Japan/305/57 sequence at aa 215 rendering it unrecognizable by CTLs specific for HA 210-219. This protocol was developed to select for HA 204-212 specific CTLS. In vitro restimulation was performed up to three times at 14 day intervals.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>T cell CD8+</CellType>
                            <CellCultureConditions>Cell Line / Clone</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Other</CellTissueType>
                            <CellType>P815-Mast cell</CellType>
                            <CellCultureConditions>Cell Line / Clone</CellCultureConditions>
                            <AutologousOrSyngeneic>N</AutologousOrSyngeneic>
                            <SourceOrganismId>10090</SourceOrganismId>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>124</MhcAlleleId>
                            <MhcEvidenceCode>T cell assay -Single MHC type present</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>HA204-212</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>LYQNVGTYV</LinearSequence>
                                        <StartingPosition>204</StartingPosition>
                                        <EndingPosition>212</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P03451.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>11320</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>67</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Target cells presenting the epitope were lysed by the CTL cell line restimulated in vitro either 1 or 3 times with influenza virusA/Ann Arbor/57 which differs from the A/Japan/305/57 sequence at aa 215 rendering it unrecognizable by CTLs specific for HA 210-219. This protocol was developed to select for HA 204-212 specific CTLS. This lysis was demonstrated to be dose-dependent and similar to that of a HA210-219 specific CTL line similarly stimulated in vitro 3 times.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 1A</LocationOfData>
                        <TCellId>9176</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10090</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Child</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>387161</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Influenza A/Japan/305/57</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intraperitoneal (i.p.)</Route>
                            </FirstInVivoProcess>
                            <InVitroAdministration>
                                <ProcessType>Restimulation in vitro</ProcessType>
                                <ResponderCellType>T cell CD8+</ResponderCellType>
                                <StimulatorCellType>Splenocyte</StimulatorCellType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>11320</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </InVitroAdministration>
                            <ImmunizationComments>CTL clone E2 was created from isolated pCTLs primed with infuenza virus (A/Japan/305/57) and restimulated with irradiated BALB/c splenocytes infected with influenza virus.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>T cell CD8+</CellType>
                            <CellCultureConditions>Cell Line / Clone</CellCultureConditions>
                        </EffectorCells>
                        <MhcAllele>
                            <MhcAlleleId>124</MhcAlleleId>
                            <MhcEvidenceCode>T cell assay -Single MHC type present</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>HA204-212</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>LYQNVGTYV</LinearSequence>
                                        <StartingPosition>204</StartingPosition>
                                        <EndingPosition>212</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P03451.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>11320</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>47</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>CTL clone E2 was found to be epitope specific through positive tetramer staining.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>HA210-219</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>TYVSVGTSTL</LinearSequence>
                        <StartingPosition>210</StartingPosition>
                        <EndingPosition>219</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>P03451.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>11320</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Author communication</LocationOfData>
                <EpitopeId>67501</EpitopeId>
                <ReferenceStartingPosition>210</ReferenceStartingPosition>
                <ReferenceEndingPosition>219</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <Assays>
                    <TCell>
                        <LocationOfData>Figures 3B, 5B,  8B, and table II</LocationOfData>
                        <TCellId>10623</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>TYVSVGTSTL</LinearSequence>
                                            <StartingPosition>210</StartingPosition>
                                            <EndingPosition>219</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>P03451.1</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>11320</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>HA A-</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <RecombinantOrganism>
                                        <SubType>Recombinant Organism</SubType>
                                        <RecombinantOrganismId>10245</RecombinantOrganismId>
                                    </RecombinantOrganism>
                                </ImmunogenContainingObject>
                                <Route>Intraperitoneal (i.p.)</Route>
                            </FirstInVivoProcess>
                            <InVitroAdministration>
                                <ProcessType>Restimulation in vitro</ProcessType>
                                <ResponderCellType>Splenocyte</ResponderCellType>
                                <StimulatorCellType>Splenocyte</StimulatorCellType>
                            </InVitroAdministration>
                            <ImmunizationComments>To create the CTL line used in this assay, mice were immunized with a recombinant vaccinia virus expressing the A/Japan/305/57 HA protein lacking the immunodominant transmembrane region (HA A-). Splenocytes were then stimulated in vitro with APC infected with APC infected with Influenza strain A/Guiyang/57-variant 17 which differs from the A/Japan/305/57 sequence at aa 207 rendering it unrecognizable by CTLs specific for HA 204-212. This protocol was developed to select for HA 210-219 specific CTLS. In vitro restimulation was performed up to 8 times at 14 day intervals.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>T cell CD8+</CellType>
                            <CellCultureConditions>Cell Line / Clone</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Other</CellTissueType>
                            <CellType>P815-Mast cell</CellType>
                            <CellCultureConditions>Cell Line / Clone</CellCultureConditions>
                            <AutologousOrSyngeneic>N</AutologousOrSyngeneic>
                            <SourceOrganismId>10090</SourceOrganismId>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>124</MhcAlleleId>
                            <MhcEvidenceCode>T cell assay -Single MHC type present</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>HA210-219</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>TYVSVGTSTL</LinearSequence>
                                        <StartingPosition>210</StartingPosition>
                                        <EndingPosition>219</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P03451.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>11320</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>67</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Target cells presenting the epitope were lysed by the CTL cell line restimulated in vitro either 1, 3, or 8 times with APC infected with Influenza strain A/Guiyang/57-variant 17 which differs from the A/Japan/305/57 sequence at aa 207 rendering it unrecognizable by CTLs specific for HA 204-212. This protocol was developed to select for HA 210-219 specific CTLS. Lysis increased with increased rounds of in vitro stimulation, was demonstrated to be dose-dependent, and found to be similar to that of a HA204-212 specific CTL line  stimulated 3 times in vitro.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Figures 3D and 5D</LocationOfData>
                        <TCellId>10624</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>TYVSVGTSTL</LinearSequence>
                                            <StartingPosition>210</StartingPosition>
                                            <EndingPosition>219</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>P03451.1</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>11320</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>HA A-</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <RecombinantOrganism>
                                        <SubType>Recombinant Organism</SubType>
                                        <RecombinantOrganismId>10245</RecombinantOrganismId>
                                    </RecombinantOrganism>
                                </ImmunogenContainingObject>
                                <Route>Intraperitoneal (i.p.)</Route>
                            </FirstInVivoProcess>
                            <InVitroAdministration>
                                <ProcessType>Restimulation in vitro</ProcessType>
                                <ResponderCellType>Splenocyte</ResponderCellType>
                                <StimulatorCellType>Splenocyte</StimulatorCellType>
                            </InVitroAdministration>
                            <ImmunizationComments>To create the CTL line used in this assay, mice were immunized with a recombinant vaccinia virus expressing the A/Japan/305/57 HA protein lacking the immunodominant transmembrane region (HA A-). Splenocytes were then stimulated in vitro with APC infected with Influenza strain A/Guiyang/57-variant 17 which differs from the A/Japan/305/57 sequence at aa 207 rendering it unrecognizable by CTLs specific for HA 204-212. This protocol was developed to select for HA 210-219 specific CTLS. In vitro restimulation was performed up to three times at 14 day intervals.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>T cell CD8+</CellType>
                            <CellCultureConditions>Cell Line / Clone</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Other</CellTissueType>
                            <CellType>P815-Mast cell</CellType>
                            <CellCultureConditions>Cell Line / Clone</CellCultureConditions>
                            <AutologousOrSyngeneic>N</AutologousOrSyngeneic>
                            <SourceOrganismId>10090</SourceOrganismId>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>124</MhcAlleleId>
                            <MhcEvidenceCode>T cell assay -Single MHC type present</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>HA210-219</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>TYVSVGTSTL</LinearSequence>
                                        <StartingPosition>210</StartingPosition>
                                        <EndingPosition>219</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P03451.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>11320</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>53</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>IFNg was produced in response to epitope presentation  by a CTL cell line restimulated in vitro either 1 or 3 times with APC infected with Influenza strain A/Guiyang/57-variant 17 which differs from the A/Japan/305/57 sequence at aa 207 rendering it unrecognizable by CTLs specific for HA 204-212. This protocol was developed to select for HA 210-219 specific CTLS. This IFNg production was lower than that produced by a HA204-212 specific CTL line similarly stimulated in vitro after one round of stimulation, but was similar after three rounds of in vitro stimulation with the corresponding epitope.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Figures 2C, 4, 6, 8C, 10, Table 1</LocationOfData>
                        <TCellId>10622</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>TYVSVGTSTL</LinearSequence>
                                            <StartingPosition>210</StartingPosition>
                                            <EndingPosition>219</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>P03451.1</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>11320</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>HA A-</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <RecombinantOrganism>
                                        <SubType>Recombinant Organism</SubType>
                                        <RecombinantOrganismId>10245</RecombinantOrganismId>
                                    </RecombinantOrganism>
                                </ImmunogenContainingObject>
                                <Route>Intraperitoneal (i.p.)</Route>
                            </FirstInVivoProcess>
                            <InVitroAdministration>
                                <ProcessType>Restimulation in vitro</ProcessType>
                                <ResponderCellType>Splenocyte</ResponderCellType>
                                <StimulatorCellType>Splenocyte</StimulatorCellType>
                            </InVitroAdministration>
                            <ImmunizationComments>To create the cells used in this assay, mice were immunized with a recombinant vaccinia virus expressing the A/Japan/305/57 HA protein lacking the immunodominant transmembrane region (HA A-). Splenocytes were then stimulated in vitro 1, 2, or 3 times with APC infected with Influenza strain A/Guiyang/57-variant 17 which differs from the A/Japan/305/57 sequence at aa 207 rendering it unrecognizable by CTLs specific for HA 204-212. This protocol was developed to select for HA 210-219 specific CTLS.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>T cell CD8+</CellType>
                            <CellCultureConditions>Short Term Restimulated</CellCultureConditions>
                        </EffectorCells>
                        <MhcAllele>
                            <MhcAlleleId>124</MhcAlleleId>
                            <MhcEvidenceCode>T cell assay -Single MHC type present</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>HA210-219</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>TYVSVGTSTL</LinearSequence>
                                        <StartingPosition>210</StartingPosition>
                                        <EndingPosition>219</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P03451.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>11320</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>47</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>To create the cells used in this assay, mice were immunized with a recombinant vaccinia virus expressing the A/Japan/305/57 HA protein lacking the immunodominant transmembrane region (HA A-). Splenocytes were then stimulated in vitro 1, 2 or 3 times with APC infected with Influenza strain A/Guiyang/57-variant 17 which differs from the A/Japan/305/57 sequence at aa 207 rendering it unrecognizable by CTLs specific for HA 204-212. This protocol was developed to select for HA 210-219 specific CTLS which bound tetramers presenting the epitope. The number of CD8+ tetramer + cells increased with each round of in vitro stimulation with 58% of the cells being positive after three stimulations.The tetramer positive cells were also increasingly of the activated phenotype, CD44hi CD62Llo (95% of the cells after three stimulations). The tetramer positive cells were sorted and found to have lower cytolytic activity than tetramer negative and the unsorted populations. Tetramer negative cells were sorted and shown to proliferate in response to the epitope and give rise to tetramer positive cells.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 1B</LocationOfData>
                        <TCellId>10621</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10090</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Child</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>387161</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Influenza A/Japan/305/57</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intraperitoneal (i.p.)</Route>
                            </FirstInVivoProcess>
                            <InVitroAdministration>
                                <ProcessType>Restimulation in vitro</ProcessType>
                                <ResponderCellType>T cell CD8+</ResponderCellType>
                                <StimulatorCellType>Splenocyte</StimulatorCellType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>11320</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </InVitroAdministration>
                            <ImmunizationComments>CTL clone D4 was created from isolated pCTLs primed with infuenza virus (A/Japan/305/57) and restimulated with irradiated BALB/c splenocytes infected with influenza virus.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>T cell CD8+</CellType>
                            <CellCultureConditions>Cell Line / Clone</CellCultureConditions>
                        </EffectorCells>
                        <MhcAllele>
                            <MhcAlleleId>124</MhcAlleleId>
                            <MhcEvidenceCode>T cell assay -Single MHC type present</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>HA210-219</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>TYVSVGTSTL</LinearSequence>
                                        <StartingPosition>210</StartingPosition>
                                        <EndingPosition>219</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P03451.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>11320</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>47</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>CTL clone D4 was found to be epitope specific through positive tetramer staining.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
        </Epitopes>
    </Reference>
</References>

